Jan 18, 2022| Posted in: Cancers, Drug Development, Treatment

Albumin-Bound Sirolimus: Newly-Approved Treatment for PEComa

Brendan Delaney, Chief Operating Officer of Aadi Bioscience,…
Jan 13, 2022| Posted in: Cancers, Diagnosis, Drug Development, Hematologic Disorders, Treatment

What Physicians Can Learn About CML Treatment from the OPTIC Trial 

Dr. Thihan Padukkavidana of Takeda Oncology discusses what…
Jan 6, 2022| Posted in: Cancers, Diagnosis, Drug Development, Hematologic Disorders

Disease-Free Survival vs. Progression-Free Survival in Cancer Studies

Dr Paolo Ghia discusses the difference between disease-free…
Dec 23, 2021| Posted in: Cancers, Drug Development, Hematologic Disorders, News

Sustained uMRD Demonstrated in Elderly CLL Patients Receiving Ibrutinib Plus Venetoclax

Dr. Arnon Kater from the University of Amsterdam discusses new…
Dec 22, 2021| Posted in: Cancers, Diagnosis, Drug Development

PEComa: Disease Overview and Previous Approach to Care

Brendan Delaney, Chief Operating Officer of Aadi Bioscience,…
Dec 20, 2021| Posted in: Cancers, Hematologic Disorders, News

Subasumstat + Rituximab Is Tolerable in Subsets of Non-Hodgkin Lymphoma Patients

Karuppiah Kannan, Senior Director at Takeda, discusses early…

Cutaneous T-Cell Lymphoma Learning Center

Cutaneous T-cell lymphoma (CTCL) belongs to the non-Hodgkin lymphoma class of hematologic T-cell lymphoproliferative disorders. It is a rare group of malignancies, with an incidence of 6.4 cases per 1 million people.

Tenosynovial Giant Cell Tumor (TGCT)

Tenosynovial giant cell tumor (TGCT) is a non-malignant tumor involving the joint synovium, bursae, and tendon sheath. These rare tumors are sometimes referred to as giant cell tumor of the tendon sheath (GCT-TS) and/or pigmented villonodular synovitis (PVNS).

Drug Compounding: What Physicians and Patients Need to Know

Drug compounding is often regarded as the process of combining, mixing, or altering ingredients to create a medication tailored to the needs of an individual patient. This can be especially relevant for rare disease patients. For more information on drug compounding including FDA resources, visit the CheckRare Drug Compounding Resource page.

Preclinical Studies and Clinical Trials Towards Individualized Therapies

In this CME program, Drs. Ari Zimran, Gustavo Maegawa, and Nina Raben, MD discuss preclinical studies and clinical trials regarding individualized therapies.

Novel Technologies and Emerging Therapies for Precision Medicine

In this CME program, Drs. Shoshana Revel-Vilk and Neil Joseph Weinreb discuss novel technologies and mmerging therapies for precision medicine.

Gaucher Disease Research Highlights

Derralynn Hughes, MD discusses Gaucher disease data presented at American Society of Hematology Annual Meeting (ASH 2020).

Acromegaly Highlights from ENDO 2021

Maria Fleseriu, MD, FACE highlights the latest research about Acromegaly that was presented at ENDO 2021.

WHIM Syndrome Learning Center

WHIM syndrome is a rare, congenital primary immunodeficiency disorder associated with severe neutropenia that affects all ages. However, due to the heterogeneous presentation of the disease, coupled with lack of awareness of the condition, the diagnosis may be delayed, sometimes even into adulthood.

Aromatic L-Amino Acid Decarboxylase (AADC) Deficiency Learning Center

Aromatic L-amino acid decarboxylase (AADC) deficiency is a rare, genetic disorder that affects the central nervous systems of young patients.